Sarcoidosis drug study halted after just 3 patients
NCT ID NCT02134717
First seen Dec 16, 2025 · Last updated May 18, 2026 · Updated 18 times
Summary
This study aimed to see if the drug maraviroc could reduce inflammation in the lungs of people with sarcoidosis. Participants took the drug for 6 weeks and had two lung exams to measure immune cells. The study was stopped early and only enrolled 3 people, so no clear conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dorothy P. and Richard P. Simmons center for Interstitial lung Disease at the University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.